{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-002909","form_type":"8-K","ticker":null,"cik":"0001792581","company_name":"Kiromic Biopharma, Inc.","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.551659+00:00","generated_at":"2026-06-04T23:56:09.628340+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kiromic BioPharma issues $2M 25% senior secured convertible note due 2025","bullets":["Principal $2,000,000, interest 25% p.a., matures March 7, 2025.","Secured by all intellectual property, fixtures, and equipment.","Convertible at $2.50 per share; 9.99% beneficial ownership limit applies.","Default rate rises to 27%; events include non-payment or bankruptcy.","Issued to accredited investor under Section 4(a)(2) exemption."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-002909","json":"https://secwatch.observer/filing/0001558370-24-002909.json","markdown":"https://secwatch.observer/filing/0001558370-24-002909.md","text":"https://secwatch.observer/filing/0001558370-24-002909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024002909/0001558370-24-002909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024002909/krbp-20240307x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:56:09.628340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"de7422eeb992ed1f143c24b00c9bfab91a9ba331","claim":"Kiromic Biopharma, Inc. incurred senior notes of $2,000,000 at 25% per annum maturing March 7, 2025.","evidence_excerpt":"On March 7, 2024, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor. The Note has a principal amount of $2,000,000, bears interest at a rate of 25% per annum (the “Stated Rate”) and matures on March 7, 2025","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024002909/0001558370-24-002909-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"$2,000,000"},{"label":"Rate","value":"25% per annum"},{"label":"Maturity","value":"March 7, 2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"9b7a75350bc17841a1d6c123c5801fb0869a9b1d","claim":"Kiromic Biopharma, Inc. entered into 25% Senior Secured Convertible Promissory Note with an accredited investor valued at principal amount of $2,000,000 (effective 2024-03-07).","evidence_excerpt":"On March 7, 2024, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor. The Note has a principal amount of $2,000,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024002909/0001558370-24-002909-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Value","value":"principal amount of $2,000,000"},{"label":"Effective","value":"2024-03-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}